1. Home
  2. VIR vs UDMY Comparison

VIR vs UDMY Comparison

Compare VIR & UDMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIR
  • UDMY
  • Stock Information
  • Founded
  • VIR 2016
  • UDMY 2009
  • Country
  • VIR United States
  • UDMY United States
  • Employees
  • VIR N/A
  • UDMY N/A
  • Industry
  • VIR Biotechnology: Pharmaceutical Preparations
  • UDMY Other Consumer Services
  • Sector
  • VIR Health Care
  • UDMY Real Estate
  • Exchange
  • VIR Nasdaq
  • UDMY Nasdaq
  • Market Cap
  • VIR 844.9M
  • UDMY 904.2M
  • IPO Year
  • VIR 2019
  • UDMY 2021
  • Fundamental
  • Price
  • VIR $5.41
  • UDMY $6.77
  • Analyst Decision
  • VIR Strong Buy
  • UDMY Buy
  • Analyst Count
  • VIR 7
  • UDMY 11
  • Target Price
  • VIR $33.57
  • UDMY $9.90
  • AVG Volume (30 Days)
  • VIR 1.0M
  • UDMY 1.1M
  • Earning Date
  • VIR 05-07-2025
  • UDMY 04-30-2025
  • Dividend Yield
  • VIR N/A
  • UDMY N/A
  • EPS Growth
  • VIR N/A
  • UDMY N/A
  • EPS
  • VIR N/A
  • UDMY N/A
  • Revenue
  • VIR $20,861,000.00
  • UDMY $790,019,000.00
  • Revenue This Year
  • VIR N/A
  • UDMY $2.96
  • Revenue Next Year
  • VIR $10.65
  • UDMY $5.52
  • P/E Ratio
  • VIR N/A
  • UDMY N/A
  • Revenue Growth
  • VIR N/A
  • UDMY 5.43
  • 52 Week Low
  • VIR $4.95
  • UDMY $5.68
  • 52 Week High
  • VIR $14.45
  • UDMY $10.61
  • Technical
  • Relative Strength Index (RSI)
  • VIR 35.98
  • UDMY 48.74
  • Support Level
  • VIR $5.83
  • UDMY $6.21
  • Resistance Level
  • VIR $6.29
  • UDMY $7.06
  • Average True Range (ATR)
  • VIR 0.31
  • UDMY 0.27
  • MACD
  • VIR 0.02
  • UDMY 0.08
  • Stochastic Oscillator
  • VIR 28.80
  • UDMY 75.21

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About UDMY Udemy Inc.

Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.

Share on Social Networks: